financetom
Business
financetom
/
Business
/
Storyboard: Saurabh Varma on Wondrlab & plans ahead for his new setup
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Storyboard: Saurabh Varma on Wondrlab & plans ahead for his new setup
Apr 3, 2021 5:25 AM

Former Publicis CEO Saurabh Varma launched Wondrlab in November 2020, along Vandana Verma and Rakesh Hinduja, all former Publicis Groupe management level members.

In an interview to Storyboard’s Shibani Gharat, Saurabh Varma, founder & CEO of Wondrlab India, spoke at length about the plans ahead and what was it like to set up his own venture in a pandemic year.

Varma said he is here to not just set up another agency but to build a network. And, his first acquisition was Amit Akali’s What’s Your Problem (WYP).

For entire interview, watch the video

(Edited by : Bivekananda Biswas)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Major banks explore issuing stablecoin pegged to G7 currencies
Major banks explore issuing stablecoin pegged to G7 currencies
Oct 10, 2025
* Group includes US, UK, Swiss, Japanese, Canadian lenders * Banks seeking to find their way as stablecoin demand grows * Announcement follows European bank initiative last month (Adds details from paragraph 2 onwards) Oct 10 (Reuters) - A group of banks including Bank of America ( BAC ) , Citi, Deutsche Bank, Goldman Sachs ( GS ) and UBS...
Shuttle Executes LOI with Molecule.ai
Shuttle Executes LOI with Molecule.ai
Oct 10, 2025
GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. ( SHPH ) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company, today announced the execution of a non-binding letter of Intent with Molecule.ai. Molecule.ai, a pioneering artificial intelligence company founded by AI scientist and researcher Dr. ZT Zhang, PhD, today announced the execution...
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
Oct 10, 2025
By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly ( LLY ) and Anglo-Swedish rival AstraZeneca ( AZN ) as the potential next in line after Pfizer ( PFE ) struck a deal with Donald Trump's administration to lower drug prices last week. Reuters spoke to seven healthcare analysts and investors. Four...
Form 8.3 - NCC Group plc
Form 8.3 - NCC Group plc
Oct 10, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: First Trust Advisors L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Copyright 2023-2026 - www.financetom.com All Rights Reserved